Steven D. Green

Roswell Park Comprehensive Cancer Center

Also affiliated with Willamette University, Bristol-Myers Squibb (Germany), AbbVie (United States), Protagonist Therapeutics (United States), Blueprint Medicines (United States), GlaxoSmithKline (United States), Merck Institute for Science Education, Merck (Singapore), Cogent (United Kingdom), Cogent Biosciences (United States), Incyte (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia”.

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

Blood Cancer Journal(2023)10.1038/s41408-023-00910-x

N/A

0DataRank · unranked

8 citations

Mina Abdelmalek, Tara Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad +10 more